Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H32N4O4 |
Molecular Weight | 416.5139 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=C(NC(=N2)C34CCC(CCC(O)=O)(CC3)CC4)C(=O)N(CCC)C1=O
InChI
InChIKey=ZWTVVWUOTJRXKM-UHFFFAOYSA-N
InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)
Molecular Formula | C22H32N4O4 |
Molecular Weight | 416.5139 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tonapofylline is a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. Oral tonapofylline over the dose range of 3 to 225 mg/day produced significant increases in sodium excretion in patients with stable heart failure without causing kaliuresis or reducing renal function. Tonapofylline may be useful in the clinical setting for the prevention of kidney failure induced by nephrotoxic agents such as cisplatin. Tonapofylline may be renoprotective in the setting of concomitant treatment with a loop-diuretic. Adverse effects were generally mild. Tonapofylline had been in phase III clinical trial for the treatment of acute heart failure. However, this development was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. | 2004 Mar |
|
Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. | 2006 Nov 30 |
|
Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. | 2007 Aug 14 |
|
Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects. | 2011 Sep |
|
Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment. | 2012 Apr |
|
Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction. | 2016 Feb |
|
Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A(1) receptor antagonists and their biological evaluation. | 2017 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17692744
3, 15, 75, or 225 mg once daily for 10 days
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:17 GMT 2023
by
admin
on
Sat Dec 16 15:51:17 GMT 2023
|
Record UNII |
83VNU4U44T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30187611
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL414157
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
9152
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
100000154912
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
216466
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
SUB128679
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
UU-148
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
340021-17-2
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
83VNU4U44T
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
DB12569
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
C96194
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|